Jpmorgan Chase & CO Senseonics Holdings, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Senseonics Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,612 shares of SENS stock, worth $4,383. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,612

Previous 159,715 90.85%

Holding current value

$4,383

Previous $63,000 92.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$0.32 - $0.49 $46,432 - $71,100	-145,103 Reduced 90.85%	14,612 $5,000
Q2 2024 Aug 12, 2024	BUY	$0.37 - $0.52 $53,688 - $75,453	145,103 Added 993.04%	159,715 $63,000
Q3 2023 Nov 14, 2023	BUY	$0.5 - $1.05 $1,750 - $3,675	3,500 Added 31.5%	14,612 $8,000
Q2 2023 Aug 11, 2023	SELL	$0.55 - $0.89 $330,539 - $534,872	-600,980 Reduced 98.18%	11,112 $8,000
Q1 2023 May 18, 2023	BUY	$0.68 - $1.25 $405,630 - $745,645	596,516 Added 3829.71%	612,092 $434,000
Q1 2023 May 11, 2023	SELL	$0.68 - $1.25 $328,095 - $603,116	-482,493 Reduced 96.87%	15,576 $11,000
Q4 2022 Feb 13, 2023	BUY	$0.96 - $1.34 $66,668 - $93,057	69,446 Added 16.2%	498,069 $513,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $2.23 $21,408 - $46,805	20,989 Added 5.15%	428,623 $565,000
Q2 2022 Aug 11, 2022	BUY	$0.94 - $1.94 $82,340 - $169,936	87,596 Added 27.37%	407,634 $420,000
Q1 2022 May 11, 2022	BUY	$1.54 - $3.71 $66,503 - $160,212	43,184 Added 15.6%	320,038 $630,000
Q4 2021 Feb 10, 2022	BUY	$2.58 - $3.91 $289,316 - $438,459	112,138 Added 68.08%	276,854 $739,000
Q3 2021 Nov 12, 2021	BUY	$2.77 - $4.05 $456,263 - $667,099	164,716 New	164,716 $558,000

Others Institutions Holding SENS

# of Institutions

142

Shares Held

59.9M

Call Options Held

393K

Put Options Held

254K

View Full List

About Senseonics Holdings, Inc.

Ticker SENS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 465,447,008
Market Cap $140M
Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with ...

More about SENS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Senseonics Holdings, Inc. Transaction History